(WIRB) A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

UCI-16-52
NCT02889900
Cancer - Corpus Uteri, Cancer - Ovary
Krishnansu Tewari
Open
Treatment
II
Adult
Local

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.